Figure 5. CTL reactivity against pLMP2 bound to R62K and R62A B*2705/09 mutants and wt molecules.

pLMP2-driven CTL lines derived from a B*2705 positive patients with AS (PIC) and two B*2709 positive individual (DE and PMC) have been tested in a 4 h standard ⁵¹chromium-release assay using HeLa transfectants expressing wt or mutants of B*2705 and B*2709 subtypes as target cells after ON treatment with pLMP2 (70 µM) or in absence of peptide. Effector/target ratio was 15∶1. Mean percentage of lysis ± SD of three separate experiments is shown here.